Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home

• Published in: Journal of autism and developmental disorders 2016-06, Vol.46 (6), p.1887-1894
• Main Authors: Ruiz, Lisa M., Damron, Mackenzie, Jones, Kyle B., Weedon, Dean, Carbone, Paul S., Bakian, Amanda V., Bilder, Deborah A.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Differences; Aged; Aged, 80 and over; Aging (Biology); Analysis; Antipsychotic agents; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Antipsychotics; Autism; Autism Spectrum Disorder - complications; Autism Spectrum Disorder - drug therapy; Autism Spectrum Disorder - metabolism; Autism Spectrum Disorders; Behavioral Science and Psychology; Body Composition; Body Weight - drug effects; Child; Child and School Psychology; Child, Preschool; Departments; Developmental Disabilities; Developmental Disabilities - complications; Developmental Disabilities - drug therapy; Developmental Disabilities - metabolism; Developmentally disabled people; Diabetes; Diabetes mellitus; Diagnosis; Dosage and administration; Drug Therapy; Drug Use; Dyslipidemia; Female; Gender Differences; Guidelines; Humans; Hypertension; Intellectual disabilities; Intellectual Disability; Intellectual Disability - complications; Intellectual Disability - drug therapy; Intellectual Disability - metabolism; Lipid metabolism; Lipids - blood; Male; Medicaid; Mental Disorders; Meta Analysis; Metabolic control; Metabolism; Middle Aged; Neurosciences; Nursing Homes; Original Paper; Patient-Centered Care; Pediatrics; Pervasive Developmental Disorders; Preventive Medicine; Psychiatry; Psychology; Public Health; Risk factors; Schizophrenia; Scientific Concepts; Sex Factors; Test Results; United States; Young Adult
• ISSN: 0162-3257; 1573-3432
• DOI: 10.1007/s10803-016-2712-x

This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender ( p  = 0.01), intellectual disability with and without autism spectrum disorder ( p  = 0.001 and p  = 0.04, respectively), and inversely associated with the youngest and oldest age categories ( p  = 0.001 and p  = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose ( p